Drug Type Bispecific T-cell Engager (BiTE)  | 
Synonyms KGX 105, KGX-105, KGX105  | 
Target  | 
Action stimulants, antagonists  | 
Mechanism CD3 stimulants(T cell surface glycoprotein CD3 stimulants), EGFR antagonists(Epidermal growth factor receptor erbB1 antagonists)  | 
Therapeutic Areas  | 
Active Indication  | 
Inactive Indication-  | 
Originator Organization  | 
Inactive Organization-  | 
License Organization-  | 
Drug Highest PhasePreclinical  | 
First Approval Date-  | 
Regulation-  | 
| Indication | Highest Phase | Country/Location | Organization | Date | 
|---|---|---|---|---|
| Colorectal Cancer | Preclinical | China   | 30 Apr 2025 | |
| Solid tumor | Preclinical | China   | 27 Apr 2023 | 






